IL270070B2 - Compounds, compositions and methods for treating or preventing acute lung injury - Google Patents

Compounds, compositions and methods for treating or preventing acute lung injury

Info

Publication number
IL270070B2
IL270070B2 IL270070A IL27007019A IL270070B2 IL 270070 B2 IL270070 B2 IL 270070B2 IL 270070 A IL270070 A IL 270070A IL 27007019 A IL27007019 A IL 27007019A IL 270070 B2 IL270070 B2 IL 270070B2
Authority
IL
Israel
Prior art keywords
pazopanib
subject
solvate
salt
day
Prior art date
Application number
IL270070A
Other languages
English (en)
Hebrew (he)
Other versions
IL270070A (https=
IL270070B1 (en
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of IL270070A publication Critical patent/IL270070A/en
Publication of IL270070B1 publication Critical patent/IL270070B1/en
Publication of IL270070B2 publication Critical patent/IL270070B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL270070A 2017-04-17 2018-04-17 Compounds, compositions and methods for treating or preventing acute lung injury IL270070B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762486232P 2017-04-17 2017-04-17
PCT/US2018/027980 WO2018195084A1 (en) 2017-04-17 2018-04-17 Compounds, compositions and methods of treating or preventing acute lung injury

Publications (3)

Publication Number Publication Date
IL270070A IL270070A (https=) 2019-12-31
IL270070B1 IL270070B1 (en) 2023-05-01
IL270070B2 true IL270070B2 (en) 2023-09-01

Family

ID=63856399

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270070A IL270070B2 (en) 2017-04-17 2018-04-17 Compounds, compositions and methods for treating or preventing acute lung injury

Country Status (7)

Country Link
US (3) US11166953B2 (https=)
EP (1) EP3612184B1 (https=)
JP (1) JP7108018B2 (https=)
CN (1) CN110753546B (https=)
CA (1) CA3060247A1 (https=)
IL (1) IL270070B2 (https=)
WO (1) WO2018195084A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166953B2 (en) 2017-04-17 2021-11-09 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
JP2023502252A (ja) * 2019-11-20 2023-01-23 イエール ユニバーシティ 虚血再灌流傷害および／または肺傷害を処置するための化合物、組成物および方法
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
US20230181582A1 (en) 2020-05-22 2023-06-15 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
CN113624978B (zh) * 2021-04-06 2023-09-19 四川大学华西医院 通过检测肺泡灌洗液及血清白蛋白来评估急性呼吸窘迫综合征/急性肺损伤及预后的试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
US20130289014A1 (en) * 2010-04-27 2013-10-31 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US20160208002A1 (en) * 2013-09-30 2016-07-21 Richard H. Gomer Compositions Associated with and Methods of Managing Neutrophil Movement

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ES2124303T3 (es) 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
BR0116452A (pt) 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2008080153A2 (en) 2006-12-22 2008-07-03 The Children's Hospital Of Philadelphia A novel protein kinase c therapy for the treatment of acute lung injury
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
WO2009111648A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
JP5823672B2 (ja) 2009-07-27 2015-11-25 国立大学法人 新潟大学 受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
JP2014503500A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
AU2012244549B2 (en) 2011-04-21 2017-04-20 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
CA2852912A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Intellectual Property Limited Pazopanib formulation
US20130195871A1 (en) 2011-12-30 2013-08-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
EP3046909A4 (en) 2013-09-17 2017-03-29 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
WO2015111947A1 (en) 2014-01-24 2015-07-30 Lg Life Sciences Ltd. Composition for preventing or treating acute lung injury and acute respiratory distress syndrome
US20150299219A1 (en) * 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
RU2017105844A (ru) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения
US11166953B2 (en) 2017-04-17 2021-11-09 Yale University Compounds, compositions and methods of treating or preventing acute lung injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
US20130289014A1 (en) * 2010-04-27 2013-10-31 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US20160208002A1 (en) * 2013-09-30 2016-07-21 Richard H. Gomer Compositions Associated with and Methods of Managing Neutrophil Movement

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAPADIA ET AL,, RISK OF LIVER TOXICITY WITH THE ANGIOGENESIS INHIBITOR PAZOPANIB IN CANCER PATIENTS, 31 December 2013 (2013-12-31) *
MCMILLAN ET AL., SIGLEC-E PROMOTES 2-INTEGRIN-DEPENDENT NADPH OXIDASE ACTIVATION TO SUPPRESS NEUTROPHIL RECRUITMENT TO THE LUNG, 31 December 2014 (2014-12-31) *

Also Published As

Publication number Publication date
US11890283B2 (en) 2024-02-06
US20210121459A1 (en) 2021-04-29
US20220040177A1 (en) 2022-02-10
WO2018195084A1 (en) 2018-10-25
CN110753546A (zh) 2020-02-04
US11166953B2 (en) 2021-11-09
CN110753546B (zh) 2023-11-10
JP2020516689A (ja) 2020-06-11
EP3612184A4 (en) 2021-01-20
CA3060247A1 (en) 2018-10-25
EP3612184B1 (en) 2024-06-05
EP3612184A1 (en) 2020-02-26
IL270070A (https=) 2019-12-31
US12544377B2 (en) 2026-02-10
JP7108018B2 (ja) 2022-07-27
IL270070B1 (en) 2023-05-01
US20240165115A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
Guan et al. Resveratrol prevents chronic intermittent hypoxia-induced cardiac hypertrophy by targeting the PI3K/AKT/mTOR pathway
Wang et al. Progress in the mechanism and targeted drug therapy for COPD
US12544377B2 (en) Compounds, compositions and methods of treating or preventing acute lung injury
Lee et al. Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression
US20220040126A1 (en) Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
Zhang et al. Hydrogen sulfide restores sevoflurane postconditioning mediated cardioprotection in diabetic rats: Role of SIRT1/Nrf2 signaling‐modulated mitochondrial dysfunction and oxidative stress
Lange et al. Role of nitric oxide in shock: the large animal perspective
US20230050861A1 (en) Compositions and methods for treating pulmonary edema or lung inflammation
Vadász et al. Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na+, K+-ATPase
Casalino-Matsuda et al. Hypercapnia suppresses macrophage antiviral activity and increases mortality of influenza A infection via Akt1
Zeng et al. Hepatic hepcidin protects against polymicrobial sepsis in mice by regulating host iron status
Cavalu et al. Unveiling citicoline's mechanisms and clinical relevance in the treatment of neuroinflammatory disorders
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
PT1919466E (pt) Formulações para tratamento de anormalidades de lipoproteína compreendendo uma estatina e um derivado de metilnicotinamida
Hobai et al. Distinct myocardial mechanisms underlie cardiac dysfunction in endotoxemic male and female mice
JP2011506516A (ja) 膵嚢胞性線維症の予防および／または対症治療のための医薬組成物
Mantell et al. Design and application of locally delivered agonists of the adenosine A2A receptor
JP2013518061A (ja) 疾患の治療に使用される化合物
Li et al. ATF3 deficiency promotes alveolar macrophage pyroptosis in sepsis-induced acute lung injury
HK40018465A (en) Compounds, compositions and methods of treating or preventing acute lung injury
HK40018465B (zh) 治疗或预防急性肺损伤的化合物、组合物和方法
IWASHITA et al. Are Saunas Beneficial or Harmful for Autosomal Dominant Polycystic Kidney Disease? Examination with Model Mouse
Schier et al. Treatment of sarin exposure
McElvaney et al. Inhaled hypertonic saline as a therapeutic strategy to dampen inflammation in cystic fibrosis
Johnson β2‐Agonists